Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FX1
- Development stage
- Preclinical
- Lead developer
- Weill Cornell Medicine
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
FX1 is a potent, selective, small-molecule inhibitor of B-cell lymphoma 6 (BCL6) that targets the BTB domain lateral groove. Developed through in silico drug design (SILCS) by researchers at Weill Cornell Medicine and the University of Maryland, FX1 binds to the BCL6 BTB domain with high affinity, disrupting its interaction with corepressors such as SMRT, NCOR, and BCOR. This disruption reactivates BCL6 target genes and suppresses BCL6-dependent cancers, particularly diffuse large B-cell lymphoma (DLBCL) and triple-negative breast cancer (TNBC). FX1 has also demonstrated anti-inflammatory properties in models of sepsis, inflammatory bowel disease (IBD), and lymphoid hyperplasia, as well as the ability to repress HIV infection in follicular helper T (Tfh) cells.
- Other names
- BCL6 inhibitor FX1BCL-6 inhibitor FX1BCL 6 inhibitor FX1
02
Targets
BCL6 (B cell lymphoma 6 protein)
Beyond the preview
Go deeper on FX1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FX1.